The company appoints Michael Engsig, a pharmaceutical professional with more than two decades of experience and a successful track record in R&D and commercial functions, as Chief Operating Officer.
Before joining Vaccibody, Michael was EVP Drug Development Counselling and Business Development at KLIFO, a Northern-European drug development consultancy with significant experience in partnering with biotech and pharmaceutical companies to advance drug development projects. Prior to this, he was Head of Central and Eastern Europe Clinical Management at PPD, a leading global contract research organization with offices in 48 countries. Having spent more than 12 years in Takeda-Nycomed, he has covered both commercial areas such as Commercial Lead, Established Products in Emerging Markets in Takeda Pharmaceuticals and a number of drug development roles including leading Nycomed’s global Clinical Trial Operations departments as Head of Clinical Operations.
In his role at KLIFO, Michael has supported Vaccibody in its development over the last two years.
“I am very pleased to welcome Michael Engsig as Chief Operating Officer of Vaccibody. Michael is a proven leader with very valuable experience across multiple aspects of drug development, including clinical development and CMC. He brings strong management experience from both biotech and pharma taking products through the development phases to successful registration and to the market. I look forward, along with the rest of the Management, to work with Michael in continuing to successfully develop Vaccibody”, said Martin Bonde, CEO of Vaccibody. “Mads Axelsen has been instrumental in steering Vaccibody’s clinical development and Vaccibody’s relations to the regulatory bodies and clinical collaboration partners. I would like to extend my gratitude and thank him for all the time and great effort he has put into guiding Vaccibody on this exciting journey”.
Michael Engsig took up his new position in Vaccibody August 1, 2019.
The CMO resigns
Mads Axelsen, Chief Medical Officer in Vaccibody, has decided to resign from his position for personal reasons. Mads has held the position as Chief Medical Officer since June 2017. He will leave Vaccibody at the end of November 2019 and a search process for a substitute is being initiated.
